Prognostic factors in node-negative male breast cancer

Eli Avisar, Elaine McParland, Damian Dicostanzo, Deborah Axelrod

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Male breast cancer has traditionally been compared with female breast cancer, using the same staging system and prognostic indicators. A variety of histochemical and pathologic factors commonly used in node-negative female breast cancer were applied to 18 node-negative male breast cancers to assess their relevance to survival. Patients and Methods: A slide review was performed for nuclear grade, lymphocytic infiltration, and lymphatic and vascular invasion. Flow cytometry was available on all the specimens. Immunohistochemistry was used to assess p53, estrogen receptors (ERs), cathepsin D, Ki-67, and c-erbB-2 (HER2/neu). A clinical correlation was performed based on chart reviews and phone interviews, recording demographics, treatment, and long-term survival. Results: The average age at diagnosis was 64 years (range, 34-85 years). There were 15 T1 lesions, 2 T2 lesions, and 1 T3 lesion. All patients had a modified radical mastectomy. None received radiation therapy. The mean follow-up was 73 months. Three patients died of their disease (17.6%), 2 patients died from unrelated reasons, 1 patient was lost to follow-up, and the other 12 patients are alive with no evidence of disease. The actuarial 5-year survival was 83%. Estrogen receptor and HER2/neu overexpression were significantly more predominant in male breast cancer than in female breast cancer. Estrogen receptor positivity was present in 17 of 18 patients and HER2/neu overexpression in 10 of 18. A positive ER status and overexpression of cathepsin or p53 were correlated with a better survival, but only ER (P = 0.026) and p53 (P = 0.023) reached statistical significance. Conclusion: In this study, ER status was the only commonly used prognostic marker for female breast cancer found to be applicable in node-negative male breast cancer.

Original languageEnglish
Pages (from-to)331-335
Number of pages5
JournalClinical Breast Cancer
Volume7
Issue number4
DOIs
StatePublished - Jan 1 2006

Fingerprint

Male Breast Neoplasms
Estrogen Receptors
Breast Neoplasms
Survival
Modified Radical Mastectomy
Cathepsins
Cathepsin D
Lost to Follow-Up
Blood Vessels
Flow Cytometry
Radiotherapy
Immunohistochemistry
Demography
Interviews

Keywords

  • Cathepsin D
  • Estrogen receptors
  • Pathologic markers

ASJC Scopus subject areas

  • Cancer Research

Cite this

Prognostic factors in node-negative male breast cancer. / Avisar, Eli; McParland, Elaine; Dicostanzo, Damian; Axelrod, Deborah.

In: Clinical Breast Cancer, Vol. 7, No. 4, 01.01.2006, p. 331-335.

Research output: Contribution to journalArticle

Avisar, E, McParland, E, Dicostanzo, D & Axelrod, D 2006, 'Prognostic factors in node-negative male breast cancer', Clinical Breast Cancer, vol. 7, no. 4, pp. 331-335. https://doi.org/10.3816/CBC.2006.n.046
Avisar, Eli ; McParland, Elaine ; Dicostanzo, Damian ; Axelrod, Deborah. / Prognostic factors in node-negative male breast cancer. In: Clinical Breast Cancer. 2006 ; Vol. 7, No. 4. pp. 331-335.
@article{aaab53979a9d4810a6708f83d059d0fa,
title = "Prognostic factors in node-negative male breast cancer",
abstract = "Background: Male breast cancer has traditionally been compared with female breast cancer, using the same staging system and prognostic indicators. A variety of histochemical and pathologic factors commonly used in node-negative female breast cancer were applied to 18 node-negative male breast cancers to assess their relevance to survival. Patients and Methods: A slide review was performed for nuclear grade, lymphocytic infiltration, and lymphatic and vascular invasion. Flow cytometry was available on all the specimens. Immunohistochemistry was used to assess p53, estrogen receptors (ERs), cathepsin D, Ki-67, and c-erbB-2 (HER2/neu). A clinical correlation was performed based on chart reviews and phone interviews, recording demographics, treatment, and long-term survival. Results: The average age at diagnosis was 64 years (range, 34-85 years). There were 15 T1 lesions, 2 T2 lesions, and 1 T3 lesion. All patients had a modified radical mastectomy. None received radiation therapy. The mean follow-up was 73 months. Three patients died of their disease (17.6{\%}), 2 patients died from unrelated reasons, 1 patient was lost to follow-up, and the other 12 patients are alive with no evidence of disease. The actuarial 5-year survival was 83{\%}. Estrogen receptor and HER2/neu overexpression were significantly more predominant in male breast cancer than in female breast cancer. Estrogen receptor positivity was present in 17 of 18 patients and HER2/neu overexpression in 10 of 18. A positive ER status and overexpression of cathepsin or p53 were correlated with a better survival, but only ER (P = 0.026) and p53 (P = 0.023) reached statistical significance. Conclusion: In this study, ER status was the only commonly used prognostic marker for female breast cancer found to be applicable in node-negative male breast cancer.",
keywords = "Cathepsin D, Estrogen receptors, Pathologic markers",
author = "Eli Avisar and Elaine McParland and Damian Dicostanzo and Deborah Axelrod",
year = "2006",
month = "1",
day = "1",
doi = "10.3816/CBC.2006.n.046",
language = "English",
volume = "7",
pages = "331--335",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Prognostic factors in node-negative male breast cancer

AU - Avisar, Eli

AU - McParland, Elaine

AU - Dicostanzo, Damian

AU - Axelrod, Deborah

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Background: Male breast cancer has traditionally been compared with female breast cancer, using the same staging system and prognostic indicators. A variety of histochemical and pathologic factors commonly used in node-negative female breast cancer were applied to 18 node-negative male breast cancers to assess their relevance to survival. Patients and Methods: A slide review was performed for nuclear grade, lymphocytic infiltration, and lymphatic and vascular invasion. Flow cytometry was available on all the specimens. Immunohistochemistry was used to assess p53, estrogen receptors (ERs), cathepsin D, Ki-67, and c-erbB-2 (HER2/neu). A clinical correlation was performed based on chart reviews and phone interviews, recording demographics, treatment, and long-term survival. Results: The average age at diagnosis was 64 years (range, 34-85 years). There were 15 T1 lesions, 2 T2 lesions, and 1 T3 lesion. All patients had a modified radical mastectomy. None received radiation therapy. The mean follow-up was 73 months. Three patients died of their disease (17.6%), 2 patients died from unrelated reasons, 1 patient was lost to follow-up, and the other 12 patients are alive with no evidence of disease. The actuarial 5-year survival was 83%. Estrogen receptor and HER2/neu overexpression were significantly more predominant in male breast cancer than in female breast cancer. Estrogen receptor positivity was present in 17 of 18 patients and HER2/neu overexpression in 10 of 18. A positive ER status and overexpression of cathepsin or p53 were correlated with a better survival, but only ER (P = 0.026) and p53 (P = 0.023) reached statistical significance. Conclusion: In this study, ER status was the only commonly used prognostic marker for female breast cancer found to be applicable in node-negative male breast cancer.

AB - Background: Male breast cancer has traditionally been compared with female breast cancer, using the same staging system and prognostic indicators. A variety of histochemical and pathologic factors commonly used in node-negative female breast cancer were applied to 18 node-negative male breast cancers to assess their relevance to survival. Patients and Methods: A slide review was performed for nuclear grade, lymphocytic infiltration, and lymphatic and vascular invasion. Flow cytometry was available on all the specimens. Immunohistochemistry was used to assess p53, estrogen receptors (ERs), cathepsin D, Ki-67, and c-erbB-2 (HER2/neu). A clinical correlation was performed based on chart reviews and phone interviews, recording demographics, treatment, and long-term survival. Results: The average age at diagnosis was 64 years (range, 34-85 years). There were 15 T1 lesions, 2 T2 lesions, and 1 T3 lesion. All patients had a modified radical mastectomy. None received radiation therapy. The mean follow-up was 73 months. Three patients died of their disease (17.6%), 2 patients died from unrelated reasons, 1 patient was lost to follow-up, and the other 12 patients are alive with no evidence of disease. The actuarial 5-year survival was 83%. Estrogen receptor and HER2/neu overexpression were significantly more predominant in male breast cancer than in female breast cancer. Estrogen receptor positivity was present in 17 of 18 patients and HER2/neu overexpression in 10 of 18. A positive ER status and overexpression of cathepsin or p53 were correlated with a better survival, but only ER (P = 0.026) and p53 (P = 0.023) reached statistical significance. Conclusion: In this study, ER status was the only commonly used prognostic marker for female breast cancer found to be applicable in node-negative male breast cancer.

KW - Cathepsin D

KW - Estrogen receptors

KW - Pathologic markers

UR - http://www.scopus.com/inward/record.url?scp=33750880308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750880308&partnerID=8YFLogxK

U2 - 10.3816/CBC.2006.n.046

DO - 10.3816/CBC.2006.n.046

M3 - Article

C2 - 17092401

AN - SCOPUS:33750880308

VL - 7

SP - 331

EP - 335

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 4

ER -